This is a particularly opportune time for innovative drug development outside the private sector.  First, the information technology (IT) revolution affords ready and cheap access to information from diverse sources for virtually everyone without respect to geographical boundaries.  Thus patients will become an increasingly major force in bringing interesting therapies to the attention of GlobalCures and in shaping its agenda, which is highly patient centric at its core.
Second, the genomics revolution has given scientists a complete “parts list” for the first time.  New technologies are allowing for monitoring of many biological variables in a patient.  These advances are allowing the medical community to start individualizing therapy.  It is the perfect time to incorporate these methods into the drug development process itself, thus saving cost, time and avoiding needless toxicity.

GlobalCures is ideally suited to capitalize on this situation, since it is not concerned about diminished financial return resulting from therapies that target narrowly defined patient populations.